Gastrointestinal Cancer

Patients with metastatic renal cell carcinoma have multiple effective frontline treatment options.

Cabozantinib plus atezolizumab did not outperform sorafenib in improving overall survival in advanced hepatocellular carcinoma.

Investigators are looking to evaluate whether immunotherapy in the frontline setting, with or without chemotherapy, might improve prognoses for advanced esophageal squamous cell carcinoma.

Patients with treatment-naïve advanced gastrointestinal stromal tumors demonstrated promising responses following treatment with the TKI imatinib plus the MEK inhibitor binimetinib.

The oral targeted therapy was linked with maintained appetite, eating habits, and physical function in patients with IDH1-mutated cholangiocarcinoma.

Patient-reported outcomes demonstrated that nivolumab plus cabozantinib was associated with improved quality of life, while sunitinib was associated with health-related deterioration, in treatment-naïve renal cell carcinoma.

Encouraging response rates were observed among patients with BRAF V600E–mutant metastatic colorectal cancer who received a triplet regimen of nivolumab, encorafenib, and cetuximab.

In a 12-month follow-up, the experimental regimen continued to provide clinical benefit to patients with esophageal cancer without compromising quality of life or exhibiting an unmanageable safety profile.

Patients with HER2-positive gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma experienced a 40% reduced risk of mortality with fam-trastuzumab deruxtecan-nxki, compared with patients who received standard therapy.

Pembrolizumab plus chemotherapy did not induce clinically meaningful survival benefit, compared with chemotherapy alone, in patients with advanced gastric or gastroesophageal junction adenocarcinoma and a PD-L1 combined positive score of 1 or higher.

The presence of Arthrobacter and fatty acid metabolism pathways in gut microbiomes may be linked to an increased risk of skin-related adverse events (AEs) in patients with advanced gastric cancer.

Checkpoint inhibitors may have clinical utility in BTC based on immunogenic features of the disease; however, limited clinical activity has been observed with single-agent therapy in the advanced setting.

Pending FDA approval, the dual immunotherapy combination could provide patients with a new treatment option which would not require any further safety requirements prior to initiation.

Disease-free survival in liver-only metastatic CRC was significantly improved by introducing adjuvant mFOLFOX6 chemotherapy to hepatectomy

Event co-chair, Syma Iqbal, MD, discusses key points from a recent OncLive® Institutional Perspectives in Cancer webinar, which focused on the evolving landscapes in gastrointestinal cancer.

Patients with various solid tumor types experienced improved antitumor immunity after adhering to a diet with severe caloric restrictions.

Between 2000 and 2018, the number of pancreatic cancer cases rose, particularly among women between the ages of 15 to 35 years.

A final analysis of the phase 3 ClarIDHy trial revealed that OS was superior in patients receiving ivosidenib, despite a high crossover rate from the placebo group.

A recent study identified some of the key challenges in coordinated care for underinsured and uninsured cancer survivors who have initiated the surveillance stage of their journey.

“Previously, this mutation has been undruggable, but this is now changing.”

An expert from The University of Texas MD Anderson Cancer Center recently highlighted the ramifications of the phase 2 ReDOS trial, the need for molecular profiling in mCRC, and ongoing research on the combination of TKIs and checkpoint inhibitors.

The Pfizer-BioNTech COVID-19 vaccine induces similar levels of COVID-19 antibodies in patients with solid cancer compared with people without cancer.

Kristin Barber, FNP-BC, AOCNP, discusses ongoing phase 1 trials aimed at targeting mutations along the MAP kinase pathway.

Cetuximab represents the first approved anti-EGFR antibody which, in combination with encorafenib, is now available to treat adults with pretreated metastatic CRC with a BRAF V600E mutation.

Patients with HER2-positive, metastatic colorectal cancer and higher HER2 expression at baseline experienced improved responses following treatment with trastuzumab deruxtecan.